Hikma is introducing naloxone hydrochloride injection, 2mg/2ml, in a prefilled syringe form. The drug is used for the emergency treatment of a known or suspected opioid overdose and is the third PFS product launched by Hikma.
The launch of this product expands Hikma’s portfolio of addiction therapy treatments, which includes, among others, a naloxone vial and Kloxxado (naloxone HCl) nasal spray 8 mg, as well as buprenorphine and methadone medication options.
[Read more: Hikma intros Kloxxado]
“As an experienced provider of addiction therapy treatments we are pleased to be able to leverage our capabilities to deliver another important new tool in this fight,” said Riad Mishlawi, president of Hikma Injectables. “Our naloxone hydrochloride injection PFS is ready-to-administer and will help improve the speed, safety and accuracy of patient care, particularly in time-sensitive situations such as an opioid overdose. We are continually investing in R&D to develop our pipeline of new products and we look forward to bringing more affordable treatment options to serve the growing needs of healthcare professionals and their patients around the world.”
[Read more: Hikma intros 2 injectables]
According to IQVIA, naloxone hydrochloride injection had a market value of roughly $23 million in the 12 months ending October 2022.